DeepMed Research

UNICANCER

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: Private

Established: 1964-01-01

Employees: 101

Market Cap: -

Website: http://www.unicancer.fr

Clinical Trials

I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations

Phase 3

Completed

Conditions: Infiltrating Urothelial Carcinoma
KRAS Gene Mutation

Interventions: Drug: Chemotherapy
Drug: Panitumumab

First Posted Date: 2016-06-30

Last Posted Date: 2021-03-09

Lead Sponsor: UNICANCER

Target Recruit Count: 133

Registration Number: NCT02818725

Locations: 🇫🇷
Chu de Nimes, Nimes, France
🇫🇷
Institut Paoli Calmettes, Marseille, France
🇫🇷
Hopital Saint Andre, Bordeaux, France

and more 14 locations

Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Phase 2

Recruiting

Conditions: Squamous Carcinoma
Penile Cancer

Interventions: Drug: Chemotherapy TIP

First Posted Date: 2016-06-29

Last Posted Date: 2024-12-04

Lead Sponsor: UNICANCER

Target Recruit Count: 37

Registration Number: NCT02817958

Locations: 🇫🇷
ICO-Paul Papin, Angers, France
🇫🇷
Chu Lyon Sud, Lyon, France
🇫🇷
Chr Besancon, Besançon, France

and more 14 locations

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: EPClin genomic test

First Posted Date: 2016-05-16

Last Posted Date: 2023-09-01

Lead Sponsor: UNICANCER

Target Recruit Count: 203

Registration Number: NCT02773004

Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Combination of ribociclib + capecitabine

First Posted Date: 2016-04-28

Last Posted Date: 2023-12-07

Lead Sponsor: UNICANCER

Target Recruit Count: 18

Registration Number: NCT02754011

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Institut de Cancérologie de l'Ouest, Saint-herblain, France

EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies

Not Applicable

Completed

Conditions: Metastatic Cancers

Interventions: Other: Blood sampling

First Posted Date: 2016-03-08

Last Posted Date: 2022-09-07

Lead Sponsor: UNICANCER

Target Recruit Count: 182

Registration Number: NCT02701907

Locations: 🇫🇷
CHU d'Angers, Angers, France
🇫🇷
Institut de Cancérologie de l'Ouest (site Paul Papin), Angers, France
🇫🇷
CHU d'Auxerre, Auxerre, France

and more 33 locations

Neoadjuvant Treatment for Advanced Rectal Carcinoma

Phase 3

Completed

Conditions: Rectal Carcinoma

Interventions: Radiation: 25 Gy
Radiation: 50 Gy
Drug: Capecitabine

First Posted Date: 2015-09-16

Last Posted Date: 2023-10-13

Lead Sponsor: UNICANCER

Target Recruit Count: 103

Registration Number: NCT02551237

Locations: 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
Institut Bergonié, Bordeaux, France
🇫🇷
CHU Henri Mondor, Créteil, France

and more 34 locations

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Phase 3

Completed

Conditions: Pancreatic Cancer
Carcinoma

Interventions: Drug: Gemcitabine
Drug: Folinic Acid
Drug: 5-Fluoro-uracil
Drug: Oxaliplatin
Drug: Irinotecan
Drug: L-folinic

First Posted Date: 2015-09-03

Last Posted Date: 2024-01-09

Lead Sponsor: UNICANCER

Target Recruit Count: 171

Registration Number: NCT02539537

Locations: 🇫🇷
Hôpital Trousseau, Chambray-les-tours, France
🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷
CHU Amiens - Hôpital Nord, Amiens, France

and more 42 locations

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: rucaparib

First Posted Date: 2015-07-22

Last Posted Date: 2021-06-08

Lead Sponsor: UNICANCER

Target Recruit Count: 41

Registration Number: NCT02505048

Locations: 🇫🇷
Centre Leon Berard, Lyon, France
🇫🇷
Institut Paoli Calmettes, Marseille, France

Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor

Not Applicable

Completed

Conditions: Metastatic Breast Cancer

Interventions: Procedure: Biopsy

First Posted Date: 2015-05-14

Last Posted Date: 2022-09-21

Lead Sponsor: UNICANCER

Target Recruit Count: 150

Registration Number: NCT02444390

Locations: 🇫🇷
Centre Léon Bérard, Lyon, France
🇫🇷
Institut Claudius Regaud, Toulouse, France
🇫🇷
Clinique Armoricaine de Radiologie, Saint-Brieuc, France

and more 9 locations

Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: FOLFIRI and cetuximab
Drug: Cetuximab

First Posted Date: 2015-04-01

Last Posted Date: 2022-03-24

Lead Sponsor: UNICANCER

Target Recruit Count: 139

Registration Number: NCT02404935

Locations: 🇫🇷
Centre Hospitalier d'Auxerre, Auxerre, France
🇫🇷
Centre Hospitalier Intercommunal Cote Basque, Bayonne, France
🇫🇷
Centre Hospitalier de Beauvais, Beauvais, France

and more 43 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy